[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2006114189A1 - Composition anti-rides - Google Patents

Composition anti-rides Download PDF

Info

Publication number
WO2006114189A1
WO2006114189A1 PCT/EP2006/003119 EP2006003119W WO2006114189A1 WO 2006114189 A1 WO2006114189 A1 WO 2006114189A1 EP 2006003119 W EP2006003119 W EP 2006003119W WO 2006114189 A1 WO2006114189 A1 WO 2006114189A1
Authority
WO
WIPO (PCT)
Prior art keywords
acteoside
wrinkle
composition
containing agent
test
Prior art date
Application number
PCT/EP2006/003119
Other languages
English (en)
Inventor
Akinori Haratake
Miki Taniguchi
Tamami Satou
Takeshi Ikemoto
Original Assignee
Indena S.P.A.
Kanebo Cosmetics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena S.P.A., Kanebo Cosmetics Inc. filed Critical Indena S.P.A.
Publication of WO2006114189A1 publication Critical patent/WO2006114189A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates to cosmetic, dietary and food additive compositions containing acteoside as an effective ingredient, for the prevention or treatment of wrinkles.
  • the skin being the outermost layer of the living body, is directly subjected to environmental influence such as exposure to UV rays, which, together with internal factors due to aging decay, are the cause of various skin affections, including wrinkles.
  • the wrinkles generated by UV rays are particularly deep and noticeable.
  • the chronic production of active oxygen species and the deterioration of the SOD activity are factors associated with wrinkle formation.
  • Acteoside is a compound widely present in plants and reported to have anti-oxidation effect (J.Agric. Food Chem., Vol.49, p3113-3119, 2001). It is known to have various functions and physiological activity as UV-absorbing agent (JP-A No. 08-119842), 5-lipoxygenase inhibitor (JP-A No. 08-59685), allergy and adult disease preventive food (JP-A No. 61-291525) and anti-discoloring agent (JP-A No. 2002-173608). Disclosure of the Invention
  • the invention is based on the finding that the topical application or the oral administration of acteoside can effectively prevent, inhibit or suppress wrinkles caused by external and/or internal factors such as UV rays and senile decay. Accordingly, the invention provides a wrinkle-preventing, inhibiting or suppressing composition (hereafter "anti-wrinkle composition”) for topical or oral administration, containing acteoside as the active ingredient.
  • anti-wrinkle composition a wrinkle-preventing, inhibiting or suppressing composition for topical or oral administration, containing acteoside as the active ingredient.
  • acteoside is contained in various plants, including plants of the Oleaceae family, Lamiaceae family, Gesneriaceae family, Orobanchaceae family and Piperaceae family, from which it can be extracted and purified.
  • acteoside may be used.
  • Fruits of Oleaceae family olive (Olea europaea L.), which are particularly rich in acteoside, are preferably used as the starting raw-material for the extractive process, irrespective of production areas, product classes, or of whether they are used for food or oil-extraction.
  • the Coratina variety is particularly preferred because of its high content of acteoside.
  • the anti-wrinkle agent contains vegetation water or the solid- and/or aqueous-phase parts obtained by pressing olive fruits.
  • the vegetation water obtained by pressing olive fruits is an aqueous solution produced in the ordinary pressing process for obtaining olive oil from olive fruits.
  • the solid-phase part which is also obtained by pressing olive fruits, contains compression residues other than the liquid phase isolated from the compressed material.
  • the aqueous-phase portion is obtained after removal of the oil phase (olive oil) from the liquid phase by centrifugation and similar.
  • the vegetation water, the solid phase part and/or aqueous-phase part can be used as obtained or preferably they undergo a purification process prior to use. For example, lipid or fibrous ingredients and seed shells are removed by filtration and centrifugation.
  • alcohols may be added to the vegetation water, or to the solid-phase and/or aqueous-phase parts, thereafter filtering and centrifuging.
  • Hydrophilic alcohols and polyhydric alcohols such as ethyl alcohol, isopropyl alcohol, 1,3-butylene glycol and propylene glycol can be used in accordance with the invention.
  • the alcohol content in the total amount is preferably in the range of 5 to 80% by weight, more preferably in the range of 10 to 40% by weight.
  • the vegetation water, the solid-phase and/or aqueous-phase parts can be concentrated or dried. Furthermore, in order to increase the content of acteoside in the vegetation water, or in the solid- and/or aqueous-phase parts, various known purification processes may be employed.
  • the content of acteoside is preferably 0.5% by weight or more, more preferably 1.0% by weight or more with respect to the total weight of the anti-wrinkle agent. When the content of acteoside is at least 0.5% by wt or more, more preferably 1.0% by wt or more, the wrinkle preventive effect is fully produced.
  • Acteoside or an acteoside-containing agent can be used in the preparation of cosmetic, dietary or food additive compositions suitable for topical or oral administration, to be used in the prevention or treatment of wrinkles.
  • the cosmetics can be applied on the skin or used as bath agents.
  • Suitable dosage forms include aqueous solutions, W/O or O/W emulsions, powders such as granules with an appropriate diluent and tablets.
  • Creams, milky lotions, face lotions, facial masks, gels, sticks, sheets and cataplasms represent suitable dosage forms.
  • the blending amount of wrinkle preventive agent in the cosmetics is largely variable depending on the dosage form; in general, the anti-wrinkle agents according to the invention, as well as acteoside alone, are mixed with the other components in the range of 0.001 to 2.0% by weight, more preferably in the range of 0.001 to 1.0% by weight of the total composition.
  • the amount is less than 0.001% by weight, the wrinkle preventive effect may not result completely satisfactory.
  • it exceeds 2% by weight in some cases the skin-feeling(for example sticky, squeaking, non- smooth feel) during use may deteriorate and, more importantly, the smell may become stronger and the dosage forms unstable.
  • the anti- wrinkle cosmetic composition according to the invention may contain various ingredients generally used in cosmetics, for instance coloring pigments such as tar dyes and iron oxides; antimicrobial agents such as paraben; anionic surfactants such as sodium cetyl sulfate; nonionic surfactants such as polyoxyethylene alkylether, polyoxyethylene fatty acid ester, polyoxyethylene polyhydric alcohol fatty acid ester, polyoxyethylen cured castor oil, polyhydric alcohol fatty acid ester and polyglycerin fatty acid ester; cationic surfactants such as tetraalky lammonium salt; amphoteric surfactants of betaine type, sulfo-betaine type, sulfo-amino acid type, and sodium N-stearoyl-L- glutamate; natural surfactants such as lecitin and lyso-phosphatidylcholine; natural polymers such as gelatin, casein
  • the anti-wrinkle compositions according to the invention may be in a form suitable for oral administration, preferably in a liquid form such as a solution, suspension or dispersion, more preferably in form of beverage.
  • the anti-wrinkle agent may be provided in solid oral compositions such as tablets, granules, capsules, jelly, chewing gums, candies and tablet candies.
  • the amount of acteoside or acteoside-containing agent may vary depending on the dosage formulation used but, in general, it is preferably in the range of 0.001 to 10% by weight, more preferably in the range of 0.001 to 5.0% by wt of the total composition. When the amount of acteoside or acteoside-containing agent is less than 0.001% by weight, the anti-wrinkle effect is scarce. On the other hand, when it exceeds 10.0% by weight, adverse affects may occurr.
  • the solid or liquid oral compositions containing acteoside or the anti- wrinkle agent according to the invention may additionally comprise adequate amounts of ingredients that are commonly used in beverages or solid oral compositions, including vitamins such as vitamin C, vitamin E, vitamin B2, vitamin B6 and nicotinamide; minerals such as magnesium, zinc and chromium; Lagerstroemia speciosa, Gymnema sylvestre, Aloaceae, Siraitia Grosvenorii, Zizania latifolia, Morus alba leaf, Eriobotrya japonica leaf, Nelumbo nucifera, Salacia spp., Rhodiola sacrs, indigestible dextrin, Echevaria grauca, green tea polyphenol, teanin, histidine, Panax ginseng, seaweed, hop, Ipomoea batatas or beer enzymes. Furthermore, emulsifiers, dispersing agents, suspension agents, spreading agents, penetrating agents, wetting agents and stabilizing agents may be combined and blended.
  • the oral administration of an appropriate amount of the anti-wrinkle agent according to the invention can effectively prevent wrinkle formation or inhibit wrinkle progression.
  • the anti-wrinkle agent is orally taken one to three times a day so that the total amount of acteoside intake is in the range of 0.001 to 0.05 g, preferably in the range of 0.001 to 0.01 g a day for an adult.
  • the daily intake is less than 0.001 g, the anti- wrinkle effect may be scarce and, on the other hand daily amounts exceeding 0.05 g do not bring particular advantages.
  • Example 1 Manufacture of acteoside crude product Two kilograms of fruits of Coratina variety olive were pressed according to an ordinary method, and a solid-phase part and an aqueous-phase part were recovered. A hydroalcoholic solution was added to the recovered solid- and aqueous-phase parts, followed by extracting twice. The obtained extract was concentrated and dried according to an ordinary method, thereby obtaining an "acteoside crude product" having an acteoside content of 5.0% by weight.
  • the anti-wrinkle agent according to the invention was applied as an external application to evaluate the wrinkle preventive effect of acteoside, according to a test based on the following photo-aging model.
  • Photoaging was induced by irradiating UVA and UVB, separately, on the back of hairless mice, once a day and 5 times a week, continuously for four weeks.
  • the amount of irradiation used each time was increased weekly stepwise, for example 20, 25 and 30 J/cm 2 for UVA and 20, 30 and 40 mJ/cm 2 for UVB, and after three weeks the amount of irradiation was fixed at the respective maximum.
  • ChromaDex Corp. and a sample containing 10% by weight acteoside crude product according to example 1, were prepared by blending with an aqueous solution of 50% by weight ethanol as a base (comparative example 1), and applied to the test animals (Examples 3 and 4).
  • the external applications were applied as frequently as the UV irradiation. Specifically, UV was irradiated once a day and followed by application to the back skin (diameter: substantially 2.5 cm) of a hairless mouse with 0.1 mL of the sample.
  • Test sample hydroxyprolin a) by weight) ( ⁇ mol/cm 2 )
  • Example 3 Acteoside 0.5 4.98 ⁇ 0.35 b) r , .
  • Acteoside crude Example 4 10.0 4.96 ⁇ 0.34 b) r product
  • Comparative drilling , , , Base alone 55.27 ⁇ 2.52 example 1 c) A numerical value shows an average value ⁇ standard deviation. d) p ⁇ 0.01 (significant difference from comparative example 1) Groups treated with acteoside and acteoside crude product according to examples 3 and 4 respectively, show significantly low numerical values of skin thickness with respect to 'comparative example 1 ' where a base alone was used (control); hence acteoside is effective in reducing skin thickness caused by photo aging.
  • acteoside in a controlled test- system, significantly reduces collagen decrease due to the photo aging and suppresses the skin thickening; hence, acteoside is considered effective in suppressing wrinkle growth.
  • the wrinkle preventive agent according to the invention was orally administered to evaluate the wrinkle preventive effect of acteoside according to a test based on the following photoaging model.
  • Photoaging was induced by irradiating UV-rays under the same conditions as used in the wrinkle preventive test by dermal administration.
  • the irradiation period was 12 weeks.
  • the wrinkle preventive effect was evaluated according to the wrinkle score.
  • the wrinkle score was determined according to the method of Bissett et al. (Photochem. Photobiol., 46:367-378,
  • acteoside manufactured by ChromaDex Corp.
  • acteoside high concentrated product according to example 2 were dispersed in a base, namely an aqueous solution of 0.5% by weight carboxymethyl cellulose (Comparative example 2), and administered to test animals (Examples 5 and 6).
  • the administration was started from five weeks after starting UV irradiation. Before starting the UV irradiation at the fixed day, the sample was directly administered into the stomach of the test animal with an oral gavagein the amounts shown in Table 3.
  • the concentrations of the respective test samples were properly adjusted to keep identical administration capacities in the respective groups. Three days after the completion of the last irradiation, the wrinkle scores were rated and the differences with the control group (base alone w/o acteoside) according to comparative example 2 were examined.
  • Example 6 concentrated product 25.0 1.60 ⁇ 0.28°
  • the wrinkle preventive agent as shown in the following example, can be supplied in different formulations (which are not limitative). Percentages of blending amounts are all % by weight.
  • Example 7 Skin lotion B ingredienst was uniformly dissolved in C ingredients, followed by uniformly blending. In the next stage, A ingredients were added thereto, followed by agitation and dispersion, and by filling in a container, whereby a skin lotion was prepared.
  • a ingredients and a B ingredient were mixed, heated and dissolved homogeneously, and then the temperature was set at 8O 0 C.
  • C ingredients were added thereto to emulsify, followed by cooling to 3O 0 C with stirring, whereby a skin cream was prepared.
  • the ingredients below were mixed, filled in a gelatin film made of gelatin and glycerin and used to prepare a soft capsule formulation according to an ordinary method.
  • the ingredients below were mixed and filled in a capsule vessel made of gelatin to prepare a hard capsule formulation according to ordinary methods.
  • the ingredients below were mixed to produce a jelly preparation according to an ordinary method.
  • the ingredients below were mixed to prepare a chewing gum according o an ordinary method.
  • the anti-wrinkle agent according to the invention when applied by dermal administered and/or orally administered, can exhibit excellent wrinkle preventive effect.
  • the anti-wrinkle agent can be formulated as aqueous solution, W/O type or O/W type emulsion, tablet, granular preparation, various kinds of capsule formulations, drink preparation, solid formulation; as a cosmetic, it can be provided in form of cream, emulsion, lotion, facial mask, gel, sticks, sheet and cataplasm; in addition it can be prepared as beverage, drink, jelly, chewing gum, candy and tablet cake.
  • the anti-wrinkle compositions of the invention can be used to prevent or treat wrinkles.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions cosmétiques, diététiques et d'additifs alimentaires contenant de l'actéoside comme substance active. Les compositions sont appropriées pour une administration orale ou topique et sont utilisables pour la prévention et le traitement de rides.
PCT/EP2006/003119 2005-04-28 2006-04-06 Composition anti-rides WO2006114189A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-132793 2005-04-28
JP2005132793A JP2006306804A (ja) 2005-04-28 2005-04-28 シワ形成抑制剤

Publications (1)

Publication Number Publication Date
WO2006114189A1 true WO2006114189A1 (fr) 2006-11-02

Family

ID=36691444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/003119 WO2006114189A1 (fr) 2005-04-28 2006-04-06 Composition anti-rides

Country Status (2)

Country Link
JP (1) JP2006306804A (fr)
WO (1) WO2006114189A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116391A1 (fr) * 2007-03-26 2008-10-02 Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou) Promoteur de la prolifération de neuroblaste et promoteur de l'excroissance de neurite
ITMI20091165A1 (it) * 2009-07-01 2011-01-02 Skinworld Lab S R L Combinazione di cellule staminali, e/o loro estratti, di lippia citriodora e leontopodium alpinum, ed il suo uso in prodotti cosmetici
JP2011102270A (ja) * 2009-11-11 2011-05-26 Rohto Pharmaceutical Co Ltd 抗糖化剤
US20110144040A1 (en) * 2009-12-10 2011-06-16 MN Intellectual Property Corp, LLC Acteoside and acteoside-rich plant extracts for increasing athletic performance in humans
US11504320B2 (en) * 2017-05-18 2022-11-22 Medena Ag Use of naturally glycosylated polyphenols as protective agents against the effects of ultraviolet irradiation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475189C (zh) * 2006-10-17 2009-04-08 王海龙 一种化妆品组合物及其制备方法和应用
JP2008280271A (ja) * 2007-05-09 2008-11-20 Oriza Yuka Kk 皮膚光老化予防剤
JP5230152B2 (ja) * 2007-09-14 2013-07-10 丸善製薬株式会社 プロフィラグリン産生促進剤及びフィラグリン産生促進剤
JP2009263279A (ja) * 2008-04-25 2009-11-12 Oriza Yuka Kk エラスターゼ阻害剤
FR2949059B1 (fr) * 2009-08-11 2012-12-28 Raphael Colicci Procede de preparation d'un jus integral d'olive, composition obtenue selon ce procede et son application dans le domaine de la cosmetique et de la dietetique
KR101356797B1 (ko) * 2012-02-02 2014-01-29 (주)모아캠 레몬버베나 유래 액티오사이드 함유 추출물 및 이를 포함하는 기능성 화장료 조성물

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07223964A (ja) * 1994-02-01 1995-08-22 Du Pont Merck Pharmaceut Co ホスホリパーゼａ２阻害剤
JPH08119842A (ja) * 1994-01-21 1996-05-14 Pola Chem Ind Inc 紫外線吸収剤
FR2772235A1 (fr) * 1997-12-12 1999-06-18 Fabre Pierre Sante Composition polyphenolique, utile comme complement alimentaire, nutraceutique ou composition cosmetique
JP2000319161A (ja) * 1999-03-09 2000-11-21 Kanebo Ltd 皮膚化粧料
WO2001034169A1 (fr) * 1999-11-11 2001-05-17 Dietrich Paper Utilisation d'un extrait de plantago lanceolata
JP2001252054A (ja) * 2000-01-07 2001-09-18 Kanebo Ltd 食品組成物
JP2002173608A (ja) * 2000-12-06 2002-06-21 Sanei Gen Ffi Inc 退色抑制剤
FR2825022A1 (fr) * 2001-05-23 2002-11-29 Seppic Sa Composition de polyphenols d'olives.utilisation comme actif cosmetique et dietetique
FR2850572A1 (fr) * 2003-02-03 2004-08-06 Rocher Yves Biolog Vegetale Utilisation du verbascoside comme agent stimulant la synthese de proteines de choc thermique par les cellules de la peau
JP2005029481A (ja) * 2003-07-09 2005-02-03 Kao Corp 経口しわ形成予防改善剤
JP2005082522A (ja) * 2003-09-08 2005-03-31 Kanebo Cosmetics Inc 美白化粧料

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08119842A (ja) * 1994-01-21 1996-05-14 Pola Chem Ind Inc 紫外線吸収剤
JPH07223964A (ja) * 1994-02-01 1995-08-22 Du Pont Merck Pharmaceut Co ホスホリパーゼａ２阻害剤
FR2772235A1 (fr) * 1997-12-12 1999-06-18 Fabre Pierre Sante Composition polyphenolique, utile comme complement alimentaire, nutraceutique ou composition cosmetique
JP2000319161A (ja) * 1999-03-09 2000-11-21 Kanebo Ltd 皮膚化粧料
WO2001034169A1 (fr) * 1999-11-11 2001-05-17 Dietrich Paper Utilisation d'un extrait de plantago lanceolata
JP2001252054A (ja) * 2000-01-07 2001-09-18 Kanebo Ltd 食品組成物
JP2002173608A (ja) * 2000-12-06 2002-06-21 Sanei Gen Ffi Inc 退色抑制剤
FR2825022A1 (fr) * 2001-05-23 2002-11-29 Seppic Sa Composition de polyphenols d'olives.utilisation comme actif cosmetique et dietetique
FR2850572A1 (fr) * 2003-02-03 2004-08-06 Rocher Yves Biolog Vegetale Utilisation du verbascoside comme agent stimulant la synthese de proteines de choc thermique par les cellules de la peau
JP2005029481A (ja) * 2003-07-09 2005-02-03 Kao Corp 経口しわ形成予防改善剤
JP2005082522A (ja) * 2003-09-08 2005-03-31 Kanebo Cosmetics Inc 美白化粧料

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "C + OleaSelect(TM)", JARROW'S FORMULAS, March 2005 (2005-03-01), pages 1 - 1, XP002392657, Retrieved from the Internet <URL:http://www.jarrow.com/product.php?prodid=267> [retrieved on 20060727] *
ANONYMOUS: "Indena introduces first olive extract", FOOD NAVIGATOR EUROPE, 19 November 2004 (2004-11-19), pages 1 - 2, XP002392656, Retrieved from the Internet <URL:http://www.foodnavigator.com/news/ng.asp?id=56191-indena-introduces-first> [retrieved on 20060727] *
ANONYMOUS: "Oleaselect TM - A highly standardized olive fruit extract", INDENA, July 2004 (2004-07-01), pages 1 - 6, XP002392658, Retrieved from the Internet <URL:http://www.indena.com/pdf/oleaselect.pdf> [retrieved on 20060727] *
ANONYMOUS: "Search results for "http://www.jarrow.com"", INTERNET ARCHIVE WAYBACK MACHINE, 27 July 2006 (2006-07-27), pages 1 - 1, XP002392676, Retrieved from the Internet <URL:http://www.archive.org/web/*/http://www.jarrow.com> [retrieved on 20060727] *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 09 30 September 1996 (1996-09-30) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31) *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 14 5 March 2001 (2001-03-05) *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 26 1 July 2002 (2002-07-01) *
PATENT ABSTRACTS OF JAPAN vol. 2002, no. 10 10 October 2002 (2002-10-10) *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116391A1 (fr) * 2007-03-26 2008-10-02 Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou) Promoteur de la prolifération de neuroblaste et promoteur de l'excroissance de neurite
TWI465237B (zh) * 2007-03-26 2014-12-21 Sinphar Pharmaceutical Co Ltd 神經芽細胞增殖促進劑及神經突起伸展劑
ITMI20091165A1 (it) * 2009-07-01 2011-01-02 Skinworld Lab S R L Combinazione di cellule staminali, e/o loro estratti, di lippia citriodora e leontopodium alpinum, ed il suo uso in prodotti cosmetici
JP2011102270A (ja) * 2009-11-11 2011-05-26 Rohto Pharmaceutical Co Ltd 抗糖化剤
US20110144040A1 (en) * 2009-12-10 2011-06-16 MN Intellectual Property Corp, LLC Acteoside and acteoside-rich plant extracts for increasing athletic performance in humans
US11504320B2 (en) * 2017-05-18 2022-11-22 Medena Ag Use of naturally glycosylated polyphenols as protective agents against the effects of ultraviolet irradiation

Also Published As

Publication number Publication date
JP2006306804A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
WO2006114189A1 (fr) Composition anti-rides
JP4693963B2 (ja) エストロゲン様作用剤、コラーゲン産生促進剤、及び線維芽細胞増殖剤
KR20180125612A (ko) 폴리페놀이 풍부한 아보카도 과육 및/또는 껍질 추출물 및 이를 포함한 화장학적, 피부과학적 및 기능식품 조성물
DE60132851T2 (de) Arzneimittel zur Vorbeugung, Linderung oder Behandlung von Hypertonie
KR20080032189A (ko) 식욕 억제를 위한 전달 시스템
JP4025578B2 (ja) 痩身用食品
JP2009263275A (ja) 抗酸化剤並びにそれを含有する化粧料、飲食品組成物及び医薬品組成物
US6896896B2 (en) Physiologically functional foods or cosmetics containing sphingoglycolipids and processes for their production
JP2011148727A (ja) しわ改善用美容セット並びにこれを使用する美容方法
JP2009084214A (ja) 糖化阻害剤
JP2002003390A (ja) 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料
JPH03193713A (ja) タンニン含有組成物
EP0867187A1 (fr) Extrait de propolis de solubilité dans l&#39; eau améliorée
US20060110475A1 (en) Composition containing in combination at least one bourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent
US7569235B2 (en) Compositions for treating and/or preventing pollinosis
JP6059510B2 (ja) セラミド産生促進剤
KR101965594B1 (ko) 콩 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물
JP5777209B2 (ja) コラーゲン産生促進剤および食品組成物
KR100478021B1 (ko) 수용성이개선된프로폴리스추출물
KR102343245B1 (ko) 감국 지용성 분획 추출물을 유효성분으로 포함하는 아토피의 예방, 개선 또는 치료용 조성물
JP4982648B2 (ja) 金属沈着抑制剤
JP4105498B2 (ja) アトピー性疾患の症状の予防・緩和に有効な組成物
JP2004149729A (ja) 抗酸化剤
JP2005089374A (ja) 血糖値上昇抑制機能性飲食品
KR102602321B1 (ko) 검정콩, 풋귤 및 울금 추출물을 포함하는 탈모 증상 예방 또는 개선용 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 06724066

Country of ref document: EP

Kind code of ref document: A1